Didn't seem to be a bad result. Haven't bothered going over the figures yet, but I'm surprised they're sub 50c. Surely they remain a target?
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%